Ribeaudeau F, Senet P, Cayuela J M, Fund X, Paul C, Robert C, Scrobohaci M L, Dubertret L
Institut de Recherche sur la Peau Service de Dermatologie, Paris, France.
Br J Dermatol. 1999 Aug;141(2):259-63. doi: 10.1046/j.1365-2133.1999.03026.x.
Hypercoagulable states have been reported to be associated with venous leg ulcers. In an attempt to investigate the prevalence of hypercoagulable states in patients with venous leg ulcers, we performed a prospective case-control study for the presence of coagulation defects in such patients, including resistance to activated protein C (APC), factor V Leiden mutation and a newly described mutation in factor II. Results were compared with those obtained in a control group. APC resistance was found in four of 33 patients tested, but only one was found to be heterozygous for the factor V Leiden mutation. Factor II mutation was found in two of 30 patients tested. Our findings show that the prevalence of coagulation abnormalities is not different in patients with venous leg ulcers from controls in our study, suggesting that only selected patients with venous ulcers and a history of recurrent deep venous thrombosis should be investigated for the presence of coagulation defects.
据报道，高凝状态与下肢静脉溃疡有关。为了调查下肢静脉溃疡患者高凝状态的患病率，我们对这类患者的凝血缺陷情况进行了一项前瞻性病例对照研究，包括对活化蛋白C（APC）的抵抗、因子V莱顿突变以及因子II中一种新描述的突变。将结果与对照组的结果进行比较。在33例接受检测的患者中，有4例发现存在APC抵抗，但只有1例被发现为因子V莱顿突变的杂合子。在30例接受检测的患者中，有2例发现存在因子II突变。我们的研究结果表明，在我们的研究中，下肢静脉溃疡患者凝血异常的患病率与对照组并无差异，这表明只有部分有静脉溃疡且有复发性深静脉血栓形成病史的患者才应接受凝血缺陷的检查。
